以政策温度力度增强民营企业发展信心

Group 1 - The core viewpoint emphasizes the importance of regular visits by regulatory bodies to understand and address the challenges faced by private listed companies, thereby enhancing policy implementation accuracy [1][2] - Regulatory departments are focusing on key issues such as how capital market tools can help private enterprises overcome development bottlenecks during their visits [1] - The visits aim to guide private listed companies in utilizing supportive policies effectively, with specific attention to mergers and acquisitions, as seen in the case of Yiling Pharmaceutical [1][2] Group 2 - Companies have reported three main categories of issues during visits: suggestions on regulatory rules, operational difficulties requiring local government coordination, and inadequate communication with investors [2] - Regulatory bodies are committed to establishing a long-term mechanism to improve the quality and effectiveness of visits, fostering a better business environment and enhancing corporate governance [2][3] - Collaboration with local governments and relevant departments is being strengthened to help listed companies resolve practical difficulties, as demonstrated by initiatives from various regional regulatory bodies [3] Group 3 - The establishment of a regular visiting mechanism by multiple departments signals strong support for listed companies to enhance their performance and promote healthy capital market development [4] - There is a call for increased financing support while also focusing on preventing bond default risks and addressing overdue payments to private listed companies [4]